This is partly due to the incomplete understanding of the mechanisms underlying mTOR activation and mTORC1 addiction in cancer cells, which compromises the identification of effective biomarkers for predicting potentially responsive patients and guiding clinical implications. Here, MTOR is linked to cancer.